Article info

PDF
Letter
Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis

Authors

  • Isabel Quintana Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Raquel Mejías-Luque Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, GermanyGerman Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany PubMed articlesGoogle scholar articles
  • Mariona Terradas Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Matilde Navarro Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Virginia Piñol Digestive Unit, Hospital Universitario de Girona Dr Josep Trueta, Girona, SpainSchool of Medicine, University of Girona, Girona, Spain PubMed articlesGoogle scholar articles
  • Pilar Mur Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Sami Belhadj Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Elia Grau Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Esther Darder Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain PubMed articlesGoogle scholar articles
  • Ares Solanes Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, Spain PubMed articlesGoogle scholar articles
  • Joan Brunet Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, SpainHereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain PubMed articlesGoogle scholar articles
  • Gabriel Capellá Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Markus Gerhard Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, GermanyGerman Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany PubMed articlesGoogle scholar articles
  • Laura Valle Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Laura Valle, Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona 08908, Spain; lvalle{at}iconcologia.net
View Full Text

Citation

Quintana I, Mejías-Luque R, Terradas M, et al
Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis

Publication history

  • Received November 22, 2017
  • Revised December 11, 2017
  • Accepted December 19, 2017
  • First published January 12, 2018.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.